DT07 Rec'd PCT/PT0 2 7 JAN 2005 ATTORNEY'S DOCKET NUMBER

FORM PTO-1390 (Modified) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE (REV. 12-2004)

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION LINDER 35 LLS C. 371

87792.017905

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/522512

		ICERINING A SUBINISS	SION UNDER 35 0.3.C. 37 1					
INTERNATIONAL APPLICATION NO. PCT/GB2003/002832			INTERNATIONAL FILING DATE 1 July 2003	PRIORITY DATE CLAIMED 27 July 2002				
TITLE	OF I	NVENTION		<u> </u>				
			Spike Protein, Polymerase and Hemagglutin	in/Esterase				
		T(S) FOR DO/EO/US						
Brow	nlie,	John; Chalker, Victoria Jane; a	nd Erles, Kerstin					
Applic	ant h	erewith submits to the United State	es Designated/Elected Office (DO/EO/US) the fo	ollowing items and other information:				
1.	\boxtimes	This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.						
2.		This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.						
3.	\boxtimes	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.						
4.		The US has been elected (Article 31).						
5.	\boxtimes	A copy of the International Application as filed (35 U.S.C. 371 (c)(2))						
		a. is attached hereto (requ	ired only if not communicated by the Internation	onal Bureau).				
		b. 🖾 has been communicate	d by the International Bureau.					
		c. is not required, as the a	pplication was filed in the United States Receiv	ring Office (RO/US).				
6.		An English language translation	of the International Application as filed (35 U.S.	C. 371(c)(2)).				
		a. is attached hereto.						
		b. \square has been previously su	bmitted under 35 U.S.C. 154(d)(4).					
7.	\boxtimes	Amendments to the claims of the	International Application under PCT Article 19	(35 U.S.C. 371 (c)(3))				
		a. are attached hereto (re-	quired only if not communicated by the Internati	ional Bureau).				
		b. \square have been communicate	ed by the International Bureau.					
		c. have not been made; h	owever, the time limit for making such amendm	ents has NOT expired.				
		d. 🛛 have not been made and will not be made.						
8.		An English language translation	of the amendments to the claims under PCT Ar	ticle 19 (35 U.S.C. 371(c)(3)).				
9.		An oath or declaration of the inve	entor(s) (35 U.S.C. 371 (c)(4)).					
10.		An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).						
11.		A copy of the International Prelim	ninary Examination Report (PCT/IPEA/409).	•				
12.	\boxtimes	A copy of the International Search Report (PCT/ISA/210).						
Ite	ems 1	3 to 23 below concern documer	nt(s) or information included:					
13.		An Information Disclosure State	ment under 37 CFR 1.97 and 1.98.					
14.		An assignment document for rec	ording. A separate cover sheet in compliance v	with 37 CFR 3.28 and 3.31 is included.				
15.	\boxtimes	A FIRST preliminary amendment.						
16.		A SECOND or SUBSEQUENT preliminary amendment.						
17.		A substitute specification.						
18.		A power of attorney and/or change of address letter.						
19.								
20.								
21.								
22.	\boxtimes	- P						
23.		□ Other items or information:						
				•				

DT01 Rec'd PCT/PTC 2 7 JAN 2005

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

15

U.S. APPLICATION NO: (if known, see, 37 GFR 1, 5) INTERNATIONAL APPLICATION NO.						N NO.	ATTORNEY'S DOCKET NUMBER			
ユリックととうよう PC				PCT/GB2003/002832			87792.017905		905	
24. The following fees are submitted:							Applicant u	se	Office use	
☐ a) Basic national fee							\$	\$300.00		
b) Examinar	ion fee			· • • •		\$200.00	\$	\$200.00		
⊠ c) Search fe	e					\$500.00	\$	\$500.00		
TOTAL OF ABOVE CALCULATIONS = \$1000.00							s s :	1,000.00		
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.										
Total Sheets				RATE						
143 - 100 =	43 /50 =		1		x \$	S 25 0.00	\$	\$250.00		
	0.00 for furnishing priority date (37 Cl		eclaration later than r	nonth	s from	the	\$	\$130.00		
CLAIMS	NUMBER F	ILED N	IUMBER EXTRA		RATI	E				
Total claims	76	- 20 =	56	х		\$50.00	\$ \$2	2,800.00		
Independent clair	ns 8	- 3=	5	х	\$	200.00	\$ \$	1,000.00		
MULTIPLE DEPE	ENDENT CLAIMS	(if applicable)		+	\$	360.00	\$	\$0.00		
		TOTA	L OF ABOVE CA	ALC	ULAT	IONS =	\$ \$	5,180.00		
Applicant classes reduced by		atus. See 37	CFR 1.27. The fees i	ndica	ited abo	ove are	\$ \$2	2,590.00		
				S	SUBT	OTAL =	\$ \$:	2,590.00		
	f \$130.00 for furnised priority date (3)		ish translation later th	an 3	0 mont	hs from	\$	\$0.00		
			TOTAL N	IATI	ONA	L FEE =	\$ \$	2,590.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +							\$	\$0.00		
			TOTAL FEI	ES E	NCL	OSED =	\$ \$	2,590.00		
Amount to be refunded:								\$		
			Amo	unt t	o be c	harged:			\$	
a. A check	in the amount of \$		to cover the a	bove	fees is	enclosed	•		 	
	charge my Deposit ate copy of this sh		10-0223	n the	amour	nt of	\$2,590.00	_ to cove	r the above fees.	
c. The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 10-0223 . A duplicate copy of this sheet is enclosed.										
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.										
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.										
							-9.T-	· ·		
Customer No. 23469 SIGNATUI										
Jaeckle Fleischmann & Mugel, LLP Susan J. 7							limian			
190 Linden Oaks Rochester, NY 14625-2812 NAME										
Tel: 585-899-2930 34,103										
Eav. 595 900 2021							TION NUMBER			
REGISTRATI							TOTA HOMBER			

CERTIFICATE OF I	MAILING BY "EXPRESS Net al.		10 Docket No 5 1 3				
Serial No. PCT/GB2003/002832	Filing Date 27 January 2005	Examiner	ec a HUI/H Groep Zrt UM 2005				
Invention: Canine Respi	iratory Coronavirus (CRCV) Spik	ce Protein, Polymerase and He	magglutinin/Esterase				
US Natl Stage Applicat	e following correspondence: ion under 35 USC 371 including 1 nt (14 pgs), authorization to charg						
		of correspondence)					
	is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37						
CFR 1.10 in an envelo	ppe addressed to: Commissioner	for Patents, P.O. Box 1450, A	Alexandria, VA 22313-1450 on				
27 January 2005 (Date)							
		Susan J. T	'imian				
		(Typed or Printed Name of Person	Mailing Correspondence)				
		Sun 9. T-	• •				
		(Signature of Person Mailin	ng Correspondence)				
		ED 139016	485 US				
		("Express Mail" Mailing					
Note: Each paper must have its own certificate of mailing.							